ABCB1 C3435T polymorphism and risk of adverse clinical events in clopidogrel treated patients: A meta-analysis

Thrombosis Research

Volumn 129, Issue 6, 2012, Pages 754-759

  Luo, Man ^a,b   Li, Jiaoxing ^a   Xu, Xiaowei ^c   Sun, Xunsha ^a   Sheng, Wenli ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b GUANGXI MEDICAL UNIVERSITY   (China)

^c WEIFANG PEOPLE'S HOSPITAL   (China)

Author keywords

ABCB1; Adverse clinical events; Clopidogrel; Meta analysis; Polymorphism

Indexed keywords

CLOPIDOGREL; MULTIDRUG RESISTANCE PROTEIN 1;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BLEEDING; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; GENETIC HETEROGENEITY; GENETIC MODEL; HOMOZYGOTE; HUMAN; ISCHEMIA; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; PUBLISHING; RISK; STENT THROMBOSIS;

ACUTE CORONARY SYNDROME; FEMALE; HUMANS; MALE; MIDDLE AGED; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; PROGNOSIS; RISK FACTORS; TICLOPIDINE;

EID: 84861329078     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2011.12.003     Document Type: Article

References (29)

1. F.G. Kushner, M. Hand, S.C. Smith Jr., S.B. King III, J.L. Anderson, and E.M. Antman focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation 120 2009 2271 2306
2. R.S. Wright, J.L. Anderson, C.D. Adams, C.R. Bridges, D.E. Casey Jr., and S.M. Ettinger ACCF/AHA focused update of the Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 57 2011 1920 1959
3. P.A. Gurbel, K.P. Bliden, B.L. Hiatt, and C.M. O'Connor Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity Circulation 107 2003 2908 2913
4. Z.M. Chen, L.X. Jiang, Y.P. Chen, J.X. Xie, H.C. Pan, and R. Peto Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial Lancet 366 2005 1607 1621
5. M.S. Sabatine, C.P. Cannon, C.M. Gibson, J.L. López-Sendón, G. Montalescot, and P. Theroux Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation N Engl J Med 352 2005 1179 1189
6. S. Yusuf, F. Zhao, S.R. Mehta, S. Chrolavicius, G. Tognoni, and K.K. Fox Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med 345 2001 494 502
7. D. Sibbing, W. Koch, D. Gebhard, T. Schuster, S. Braun, and J. Stegherr Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement Circulation 121 2010 512 518
8. A.R. Shuldiner, J.R. O'Connell, K.P. Bliden, A. Gandhi, K. Ryan, and R.B. Horenstein Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy JAMA 302 2009 849 857
9. G. Campo, L. Fileti, M. Valgimigli, M. Tebaldi, E. Cangiano, and C. Cavazza Poor response to clopidogrel: current and future options for its management J Thromb Thrombolysis 30 2010 319 331
10. P. Gros, Y.B. Ben Neriah, J.M. Croop, and D.E. Housman Isolation and expression of a complementary DNA that confers multidrug resistance Nature 323 1986 728 731
11. K.L. Fung, and M.M. Gottesman A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function Biochim Biophys Acta 1794 2009 860 871
12. D. Taubert, N. von Beckerath, G. Grimberg, A. Lazar, N. Jung, and T. Goeser Impact of P-glycoprotein on clopidogrel absorption Clin Pharmacol Ther 80 2006 486 501
13. L. Wallentin, S. James, R.F. Storey, M. Armstrong, B.J. Barratt, and J. Horrow Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial Lancet 376 2010 1320 1328
14. K.A. Tiroch, D. Sibbing, W. Koch, T. Roosen-Runge, J. Mehilli, and A. Schömig Protective effect of the CYP2C19*17 polymorphism with increased activation of clopidogrel on cardiovascular events Am Heart J 160 2010 506 512
15. J.L. Mega, S.L. Close, S.D. Wiviott, L. Shen, J.R. Walker, and T. Simon Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis Lancet 376 2010 1312 1319
16. T. Simon, C. Verstuyft, M. Mary-Krause, L. Quteineh, E. Drouet, and N. Méneveau Genetic determinants of response to clopidogrel and cardiovascular events N Engl J Med 360 2009 363 375
17. G. Campo, G. Parrinello, P. Ferraresi, B. Lunghi, M. Tebaldi, and M. Miccoli Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome J Am Coll Cardiol 57 2011 2474 2483
18. M. Spiewak, L. Malek, G. Kostrzewa, B. Kisiel, A. Serafin, and K.J. Filipiak Influence of C3435T multidrug resistance gene-1 (MDR-1) polymorphism on platelet reactivity and prognosis in patients with acute coronary syndromes Kardiol Pol 67 2009 827 834
19. M.K. Parmar, V. Torri, and L. Stewart Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints Stat Med 17 1998 2815 2834
20. S.R. Mehta, S. Yusuf, R.J. Peters, M.E. Bertrand, B.S. Lewis, and M.K. Natarajan Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study Lancet 358 2001 527 533
21. D. Aradi, A. Komócsi, A. Vorobcsuk, O. Rideg, M. Tokés-Füzesi, and T. Magyarlaki Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: Systematic review and meta-analysis Am Heart J 160 2010 543 551
22. C. Verstuyft, T. Simon, and R.B. Kim Personalized medicine and antiplatelet therapy: ready for prime time? Eur Heart J 30 2009 1943 1963
23. Kassimis G, Davlouros P, Xanthopoulou I, Stavrou EF, Athanassiadou A, Alexopoulos D. CYP2C19*2 and other genetic variants affecting platelet response to clopidogrel in patients undergoing percutaneous coronary intervention. Thromb Res 2011, doi:10.1016/j.thromres.2011.07.022.
24. O. Rideg, A. Komócsi, T. Magyarlaki, M. Tokés-Füzesi, A. Miseta, and G.L. Kovács Impact of genetic variants on post-clopidogrel platelet reactivity in patients after elective percutaneous coronary intervention Pharmacogenomics 12 2011 1269 1280
25. T. Simon, D.L. Bhatt, L. Bergougnan, C. Farenc, K. Pearson, and L. Perrin Genetic polymorphisms and the impact of a higher clopidogrel dose regimen on active metabolite exposure and antiplatelet response in healthy subjects Clin Pharmacol Ther 90 2011 287 295
26. Y.H. Jeong, I.S. Kim, Y. Park, M.K. Kang, J.S. Koh, and S.J. Hwang Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study JACC Cardiovasc Interv 3 2010 731 741
27. A. Harmsze, J.W. van Werkum, H.J. Bouman, H.J. Ruven, N.J. Breet, and J.M. Ten Berg Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation Pharmacogenet Genomics 20 2010 18 25
28. J.L. Mega, T. Simon, J.P. Collet, J.L. Anderson, E.M. Antman, and K. Bliden Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis JAMA 304 2010 1821 1830
29. A.M. Harmsze, J.W. van Werkum, J.M. Ten Berg, B. Zwart, H.J. Bouman, and N.J. Breet CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study Eur Heart J 31 2010 3046 3053